{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T15:44:16Z","timestamp":1778341456463,"version":"3.51.4"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T00:00:00Z","timestamp":1768003200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"vor","delay-in-days":27,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Guangzhou Science and Technology Plan Project","award":["No. 2023A03J1011"],"award-info":[{"award-number":["No. 2023A03J1011"]}]},{"name":"Basic and Applied Basic Research Foundation of the Guangzhou Municipal-University Joint Funding Program","award":["No. 202201020068"],"award-info":[{"award-number":["No. 202201020068"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"DOI":"10.1186\/s12882-025-04727-7","type":"journal-article","created":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T14:04:07Z","timestamp":1768053847000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Use of hydroxychloroquine to treat patients with IgA nephropathy and time to accelerated glucocorticoid tapering"],"prefix":"10.1186","volume":"27","author":[{"given":"Mingming","family":"Ma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiao","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meifen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liangmei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenxue","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingxue","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fanna","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baozhang","family":"Guan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,10]]},"reference":[{"issue":"5","key":"4727_CR1","doi-asserted-by":"publisher","first-page":"e157998","DOI":"10.1172\/jci.insight.157998","volume":"7","author":"EG Currie","year":"2022","unstructured":"Currie EG, Coburn B, Porfilio EA, Lam P, Rojas OL, Novak J, et al. Immunoglobulin A nephropathy is characterized by anticommensal humoral immune responses. JCI Insight. 2022;7(5):e157998. https:\/\/doi.org\/10.1172\/jci.insight.157998.","journal-title":"JCI Insight"},{"issue":"14","key":"4727_CR2","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.7150\/ijbs.47198","volume":"16","author":"T Gan","year":"2020","unstructured":"Gan T, Li Y, Zhou XJ, Zhang H. Immunoproteasome in IgA nephropathy: state-of-art and future perspectives. Int J Biol Sci. 2020;16(14):2518\u201326. https:\/\/doi.org\/10.7150\/ijbs.47198.","journal-title":"Int J Biol Sci"},{"issue":"12","key":"4727_CR3","doi-asserted-by":"publisher","first-page":"108525","DOI":"10.1016\/j.celrep.2020.108525","volume":"33","author":"Y Zheng","year":"2020","unstructured":"Zheng Y, Lu P, Deng Y, Wen L, Wang Y, Ma X, et al. Single-cell transcriptomics reveal immune mechanisms of the onset and progression of IgA nephropathy. Cell Rep. 2020;33(12):108525. https:\/\/doi.org\/10.1016\/j.celrep.2020.108525.","journal-title":"Cell Rep"},{"issue":"2","key":"4727_CR4","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1093\/ndt\/gfq665","volume":"26","author":"A McGrogan","year":"2011","unstructured":"McGrogan A, Franssen CF, de Vries CS. The incidence of primary glomerulonephritis worldwide: a systematic review of the literature. Nephrol Dial Transpl. 2011;26(2):414\u201330. https:\/\/doi.org\/10.1093\/ndt\/gfq665.","journal-title":"Nephrol Dial Transpl"},{"issue":"10","key":"4727_CR5","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1093\/ndt\/gfad123","volume":"38","author":"CJ Willey","year":"2023","unstructured":"Willey CJ, Coppo R, Schaefer F, Mizerska-Wasiak M, Mathur M, Schultz MJ. The incidence and prevalence of IgA nephropathy in Europe. Nephrol Dial Transpl. 2023;38(10):2340\u20139. https:\/\/doi.org\/10.1093\/ndt\/gfad123.","journal-title":"Nephrol Dial Transpl"},{"key":"4727_CR6","doi-asserted-by":"publisher","first-page":"929138","DOI":"10.3389\/fimmu.2022.929138","volume":"13","author":"J Qing","year":"2022","unstructured":"Qing J, Hu X, Li C, Song W, Tirichen H, Yaigoub H, et al. Fucose as a potential therapeutic molecule against the immune-mediated inflammation in IgA nephropathy: an unrevealed link. Front Immunol. 2022;13:929138. https:\/\/doi.org\/10.3389\/fimmu.2022.929138.","journal-title":"Front Immunol"},{"issue":"1","key":"4727_CR7","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41581-024-00854-w","volume":"21","author":"CK Cheung","year":"2025","unstructured":"Cheung CK, Alexander S, Reich HN, Selvaskandan H, Zhang H, Barratt J. The pathogenesis of IgA nephropathy and implications for treatment. Nat Rev Nephrol. 2025;21(1):9\u201323. https:\/\/doi.org\/10.1038\/s41581-024-00854-w.","journal-title":"Nat Rev Nephrol"},{"issue":"10225","key":"4727_CR8","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","volume":"395","author":"GBDCKD Collaboration","year":"2020","unstructured":"Collaboration GBDCKD. Global, regional, and National burden of chronic kidney disease, 1990\u20132017: a systematic analysis for the global burden of disease study 2017. Lancet. 2020;395(10225):709\u201333. https:\/\/doi.org\/10.1016\/S0140-6736(20)30045-3.","journal-title":"Lancet"},{"issue":"6","key":"4727_CR9","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1093\/ndt\/gfad258","volume":"40","author":"X Shen","year":"2025","unstructured":"Shen X, Chen P, Liu M, Liu L, Shi S, Zhou X, et al. Long-term outcomes of IgA nephropathy in China. Nephrol Dial Transpl. 2025;40(6):1137\u201346. https:\/\/doi.org\/10.1093\/ndt\/gfad258.","journal-title":"Nephrol Dial Transpl"},{"issue":"6","key":"4727_CR10","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1159\/000489396","volume":"47","author":"Y Lin","year":"2018","unstructured":"Lin Y, Jia J, Guo Y, He D, Zhang Y, Wang F, et al. Corticosteroid for IgA nephropathy: are they really therapeutic? Am J Nephrol. 2018;47(6):385\u201394. https:\/\/doi.org\/10.1159\/000489396.","journal-title":"Am J Nephrol"},{"issue":"3","key":"4727_CR11","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1097\/MNH.0000000000000884","volume":"32","author":"M Ghaddar","year":"2023","unstructured":"Ghaddar M, Barratt J, Barbour SJ. An update on corticosteroid treatment for IgA nephropathy. Curr Opin Nephrol Hypertens. 2023;32(3):263\u201370. https:\/\/doi.org\/10.1097\/MNH.0000000000000884.","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"5","key":"4727_CR12","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1001\/jama.2017.9362","volume":"318","author":"J Lv","year":"2017","unstructured":"Lv J, Zhang H, Wong MG, Jardine MJ, Hladunewich M, Jha V, et al. Effect of oral Methylprednisolone on clinical outcomes in patients with IgA nephropathy: the TESTING randomized clinical trial. JAMA. 2017;318(5):432\u201342. https:\/\/doi.org\/10.1001\/jama.2017.9362.","journal-title":"JAMA"},{"issue":"19","key":"4727_CR13","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1001\/jama.2022.5368","volume":"327","author":"J Lv","year":"2022","unstructured":"Lv J, Wong MG, Hladunewich MA, Jha V, Hooi LS, Monaghan H, et al. Effect of oral Methylprednisolone on decline in kidney function or kidney failure in patients with IgA nephropathy: the TESTING randomized clinical trial. JAMA. 2022;327(19):1888\u201398. https:\/\/doi.org\/10.1001\/jama.2022.5368.","journal-title":"JAMA"},{"issue":"10\u201311","key":"4727_CR14","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1159\/000519432","volume":"52","author":"MG Wong","year":"2021","unstructured":"Wong MG, Lv J, Hladunewich MA, Jha V, Hooi LS, Monaghan H, et al. The therapeutic evaluation of steroids in IgA nephropathy global (TESTING) study: trial design and baseline characteristics. Am J Nephrol. 2021;52(10\u201311):827\u201336. https:\/\/doi.org\/10.1159\/000519432.","journal-title":"Am J Nephrol"},{"issue":"10","key":"4727_CR15","doi-asserted-by":"publisher","first-page":"3211","DOI":"10.1007\/s00467-023-06052-3","volume":"38","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Hu YT, Lv JC, Zhang H. Corticosteroids in the treatment of IgA nephropathy: lessons from the TESTING trial. Pediatr Nephrol. 2023;38(10):3211\u201320. https:\/\/doi.org\/10.1007\/s00467-023-06052-3.","journal-title":"Pediatr Nephrol"},{"issue":"1","key":"4727_CR16","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1186\/s12882-020-02120-0","volume":"21","author":"C Tang","year":"2020","unstructured":"Tang C, Lv JC, Shi SF, Chen YQ, Liu LJ, Zhang H. Effect of hydroxychloroquine in patients with IgA nephropathy with insufficient responses to immunosuppressive therapy: a retrospective case-control study. BMC Nephrol. 2020;21(1):469. https:\/\/doi.org\/10.1186\/s12882-020-02120-0.","journal-title":"BMC Nephrol"},{"issue":"1","key":"4727_CR17","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1186\/s12882-019-1484-x","volume":"20","author":"YZ Yang","year":"2019","unstructured":"Yang YZ, Chen P, Liu LJ, Cai QQ, Shi SF, Chen YQ, et al. Comparison of the effects of hydroxychloroquine and corticosteroid treatment on proteinuria in IgA nephropathy: a case-control study. BMC Nephrol. 2019;20(1):297. https:\/\/doi.org\/10.1186\/s12882-019-1484-x.","journal-title":"BMC Nephrol"},{"issue":"8","key":"4727_CR18","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1007\/s40620-023-01687-9","volume":"36","author":"IR Rao","year":"2023","unstructured":"Rao IR, Kolakemar A, Shenoy SV, Prabhu RA, Nagaraju SP, Rangaswamy D, et al. Hydroxychloroquine in nephrology: current status and future directions. J Nephrol. 2023;36(8):2191\u2013208. https:\/\/doi.org\/10.1007\/s40620-023-01687-9.","journal-title":"J Nephrol"},{"issue":"6","key":"4727_CR19","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1093\/rheumatology\/kei267","volume":"45","author":"CH Jang","year":"2006","unstructured":"Jang CH, Choi JH, Byun MS, Jue DM. Chloroquine inhibits production of TNF-alpha, IL-1beta and IL-6 from lipopolysaccharide-stimulated human monocytes\/macrophages by different modes. Rheumatology (Oxford). 2006;45(6):703\u201310. https:\/\/doi.org\/10.1093\/rheumatology\/kei267.","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"4727_CR20","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1136\/annrheumdis-2016-210012","volume":"76","author":"N M\u00fcller-Calleja","year":"2017","unstructured":"M\u00fcller-Calleja N, Manukyan D, Canisius A, Strand D, Lackner KJ. Hydroxychloroquine inhibits Proinflammatory signalling pathways by targeting endosomal NADPH oxidase. Ann Rheum Dis. 2017;76(5):891\u20137. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210012.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"4727_CR21","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/nrneph.2017.69","volume":"13","author":"G Markowitz","year":"2017","unstructured":"Markowitz G. Glomerular disease: updated Oxford classification of IgA nephropathy: a new MEST-C score. Nat Rev Nephrol. 2017;13(7):385\u20136. https:\/\/doi.org\/10.1038\/nrneph.2017.69.","journal-title":"Nat Rev Nephrol"},{"issue":"27","key":"4727_CR22","doi-asserted-by":"publisher","first-page":"4391","DOI":"10.1002\/sim.7501","volume":"36","author":"PC Austin","year":"2017","unstructured":"Austin PC, Fine JP. Practical recommendations for reporting Fine-Gray model analyses for competing risk data. Stat Med. 2017;36(27):4391\u2013400. https:\/\/doi.org\/10.1002\/sim.7501.","journal-title":"Stat Med"},{"issue":"2","key":"4727_CR23","doi-asserted-by":"publisher","first-page":"267","DOI":"10.2215\/CJN.0000000000000398","volume":"20","author":"JM Kahwaji","year":"2024","unstructured":"Kahwaji JM, Yang SJ, Sim JJ, Parke CY, Lee RL. Bisphosphonate use after kidney transplantation is associated with lower fracture risk. Clin J Am Soc Nephrol. 2024;20(2):267\u201376. https:\/\/doi.org\/10.2215\/CJN.0000000000000398.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"8","key":"4727_CR24","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.34067\/KID.0000000000000189","volume":"4","author":"K Kiryluk","year":"2023","unstructured":"Kiryluk K, Freedberg DE, Radhakrishnan J, Segall L, Jacobson JS, Mathur M, et al. Global incidence of IgA nephropathy by race and ethnicity: a systematic review. Kidney360. 2023;4(8):1112\u201322. https:\/\/doi.org\/10.34067\/KID.0000000000000189.","journal-title":"Kidney360"},{"issue":"Suppl 2","key":"4727_CR25","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1111\/nep.14288","volume":"29","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Zhang H. Current Understanding and new insights in the treatment of IgA nephropathy. Nephrol (Carlton). 2024;29(Suppl 2):75\u20139. https:\/\/doi.org\/10.1111\/nep.14288.","journal-title":"Nephrol (Carlton)"},{"issue":"1","key":"4727_CR26","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1053\/j.ajkd.2018.12.036","volume":"74","author":"LJ Liu","year":"2019","unstructured":"Liu LJ, Yang YZ, Shi SF, Bao YF, Yang C, Zhu SN, et al. Effects of hydroxychloroquine on proteinuria in IgA nephropathy: a randomized controlled trial. Am J Kidney Dis. 2019;74(1):15\u201322. https:\/\/doi.org\/10.1053\/j.ajkd.2018.12.036.","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"4727_CR27","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1016\/j.ekir.2022.03.008","volume":"7","author":"S Bagchi","year":"2022","unstructured":"Bagchi S, Bhowmik D, Singh G, Agarwal SK. Hydroxychloroquine reduces proteinuria in Indian patients with IgA nephropathy. Kidney Int Rep. 2022;7(6):1443\u20134. https:\/\/doi.org\/10.1016\/j.ekir.2022.03.008.","journal-title":"Kidney Int Rep"},{"issue":"1","key":"4727_CR28","doi-asserted-by":"publisher","first-page":"e000856","DOI":"10.1136\/lupus-2022-000856","volume":"10","author":"S Fasano","year":"2023","unstructured":"Fasano S, Messiniti V, Iudici M, Coscia MA, Ciccia F. Hydroxychloroquine daily dose, hydroxychloroquine blood levels and the risk of flares in patients with systemic lupus erythematosus. Lupus Sci Med. 2023;10(1):e000856. https:\/\/doi.org\/10.1136\/lupus-2022-000856.","journal-title":"Lupus Sci Med"},{"issue":"3","key":"4727_CR29","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/s41584-020-0372-x","volume":"16","author":"E Schrezenmeier","year":"2020","unstructured":"Schrezenmeier E, D\u00f6rner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol. 2020;16(3):155\u201366. https:\/\/doi.org\/10.1038\/s41584-020-0372-x.","journal-title":"Nat Rev Rheumatol"},{"issue":"8","key":"4727_CR30","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1002\/acr.24356","volume":"73","author":"A Jorge","year":"2021","unstructured":"Jorge A, McCormick N, Lu N, Zheng Y, Esdaile J, De Vera M, et al. Hydroxychloroquine and mortality among patients with systemic lupus erythematosus in the general population. Arthritis Care Res (Hoboken). 2021;73(8):1219\u201323. https:\/\/doi.org\/10.1002\/acr.24356.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"8","key":"4727_CR31","doi-asserted-by":"publisher","first-page":"4794","DOI":"10.4049\/jimmunol.1000702","volume":"186","author":"A Kuznik","year":"2011","unstructured":"Kuznik A, Bencina M, Svajger U, Jeras M, Rozman B, Jerala R. Mechanism of endosomal TLR Inhibition by antimalarial drugs and imidazoquinolines. J Immunol. 2011;186(8):4794\u2013804. https:\/\/doi.org\/10.4049\/jimmunol.1000702.","journal-title":"J Immunol"},{"issue":"8","key":"4727_CR32","doi-asserted-by":"publisher","first-page":"e12476","DOI":"10.15252\/emmm.202012476","volume":"12","author":"EL Nirk","year":"2020","unstructured":"Nirk EL, Reggiori F, Mauthe M. Hydroxychloroquine in rheumatic autoimmune disorders and beyond. EMBO Mol Med. 2020;12(8):e12476. https:\/\/doi.org\/10.15252\/emmm.202012476.","journal-title":"EMBO Mol Med"},{"issue":"1","key":"4727_CR33","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1681\/ASN.0000000000000256","volume":"35","author":"K El Karoui","year":"2024","unstructured":"El Karoui K, Fervenza FC, De Vriese AS. Treatment of IgA nephropathy: a rapidly evolving field. J Am Soc Nephrol. 2024;35(1):103\u201316. https:\/\/doi.org\/10.1681\/ASN.0000000000000256.","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"4727_CR34","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1007\/s40620-023-01840-4","volume":"37","author":"WJ He","year":"2024","unstructured":"He WJ, Wang J, Liu N, Li GY, Zhu XW, Yao L, et al. The efficacy and safety of hydroxychloroquine versus Leflunomide in patients with IgA nephropathy: a single-center experience. J Nephrol. 2024;37(4):933\u201340. https:\/\/doi.org\/10.1007\/s40620-023-01840-4.","journal-title":"J Nephrol"},{"issue":"3","key":"4727_CR35","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/s41419-018-0378-3","volume":"9","author":"TT Tang","year":"2018","unstructured":"Tang TT, Lv LL, Pan MM, Wen Y, Wang B, Li ZL, et al. Hydroxychloroquine attenuates renal ischemia\/reperfusion injury by inhibiting cathepsin mediated NLRP3 inflammasome activation. Cell Death Dis. 2018;9(3):351. https:\/\/doi.org\/10.1038\/s41419-018-0378-3.","journal-title":"Cell Death Dis"},{"issue":"3","key":"4727_CR36","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.xkme.2021.02.007","volume":"3","author":"S Manabe","year":"2021","unstructured":"Manabe S, Mochizuki T, Sato M, Kataoka H, Taneda S, Honda K, et al. Lupus nephritis and hydroxychloroquine-associated zebra bodies: not just in Fabry disease. Kidney Med. 2021;3(3):442\u20136. https:\/\/doi.org\/10.1016\/j.xkme.2021.02.007.","journal-title":"Kidney Med"},{"issue":"12","key":"4727_CR37","doi-asserted-by":"publisher","first-page":"678","DOI":"10.3390\/toxins15120678","volume":"15","author":"B Bosquetti","year":"2023","unstructured":"Bosquetti B, Santana AA, Greg\u00f3rio PC, Cunha R, Miniskiskosky G, Budag J, et al. The role of \u03b13\u03b21 integrin modulation on Fabry disease podocyte injury and kidney impairment. Toxins (Basel). 2023;15(12):678. https:\/\/doi.org\/10.3390\/toxins15120678.","journal-title":"Toxins (Basel)"},{"issue":"2","key":"4727_CR38","doi-asserted-by":"publisher","first-page":"2397046","DOI":"10.1080\/0886022X.2024.2397046","volume":"46","author":"Y Shi","year":"2024","unstructured":"Shi Y, Yang T, Feng Y, Li N, Shao Q, Jiang C, et al. Early reduction in total cholesterol to high-density lipoprotein cholesterol ratio predicts hydroxychloroquine efficacy in treating IgA nephropathy. Ren Fail. 2024;46(2):2397046. https:\/\/doi.org\/10.1080\/0886022X.2024.2397046.","journal-title":"Ren Fail"},{"issue":"1","key":"4727_CR39","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1080\/0886022X.2021.1997766","volume":"43","author":"G Stefan","year":"2021","unstructured":"Stefan G, Mircescu G. Hydroxychloroquine in IgA nephropathy: a systematic review. Ren Fail. 2021;43(1):1520\u20137. https:\/\/doi.org\/10.1080\/0886022X.2021.1997766.","journal-title":"Ren Fail"},{"issue":"10","key":"4727_CR40","doi-asserted-by":"publisher","first-page":"5421","DOI":"10.3390\/ijms25105421","volume":"25","author":"S von Hofsten","year":"2024","unstructured":"von Hofsten S, Fenton KA, Pedersen HL. Human and murine Toll-like receptor-driven disease in systemic lupus erythematosus. Int J Mol Sci. 2024;25(10):5421. https:\/\/doi.org\/10.3390\/ijms25105421.","journal-title":"Int J Mol Sci"},{"issue":"8","key":"4727_CR41","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1080\/15548627.2018.1474314","volume":"14","author":"M Mauthe","year":"2018","unstructured":"Mauthe M, Orhon I, Rocchi C, Zhou X, Luhr M, Hijlkema KJ, et al. Chloroquine inhibits autophagic flux by decreasing autophagosome-lysosome fusion. Autophagy. 2018;14(8):1435\u201355. https:\/\/doi.org\/10.1080\/15548627.2018.1474314.","journal-title":"Autophagy"},{"issue":"4","key":"4727_CR42","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1111\/j.1365-3083.2006.01737.x","volume":"63","author":"E Toubi","year":"2006","unstructured":"Toubi E, Kessel A, Rosner I, Rozenbaum M, Paran D, Shoenfeld Y. The reduction of serum B-lymphocyte activating factor levels following quinacrine add-on therapy in systemic lupus erythematosus. Scand J Immunol. 2006;63(4):299\u2013303. https:\/\/doi.org\/10.1111\/j.1365-3083.2006.01737.x.","journal-title":"Scand J Immunol"},{"issue":"6","key":"4727_CR43","doi-asserted-by":"publisher","first-page":"847","DOI":"10.3899\/jrheum.200685","volume":"48","author":"WM Lambers","year":"2021","unstructured":"Lambers WM, Westra J, Bootsma H, de Leeuw K. Hydroxychloroquine suppresses interferon-inducible genes and B cell activating factor in patients with incomplete and new-onset systemic lupus erythematosus. J Rheumatol. 2021;48(6):847\u201351. https:\/\/doi.org\/10.3899\/jrheum.200685.","journal-title":"J Rheumatol"},{"issue":"1","key":"4727_CR44","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1053\/j.ajkd.2019.01.026","volume":"74","author":"LJ Liu","year":"2019","unstructured":"Liu LJ, Yang YZ, Shi SF, Bao YF, Yang C, Zhu SN, et al. Effects of hydroxychloroquine on proteinuria in IgA nephropathy: A randomized controlled trial. Am J Kidney Dis. 2019;74(1):15\u201322. https:\/\/doi.org\/10.1053\/j.ajkd.2019.01.026.","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"4727_CR45","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1159\/000535864","volume":"55","author":"VA Luyckx","year":"2024","unstructured":"Luyckx VA, Elmaghrabi A, Sahay M, Scholes-Robertson N, Sola L, Speare T, et al. Equity and quality of global chronic kidney disease care: what are we waiting for? Am J Nephrol. 2024;55(3):298\u2013315. https:\/\/doi.org\/10.1159\/000535864.","journal-title":"Am J Nephrol"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-025-04727-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04727-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04727-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T15:24:03Z","timestamp":1770391443000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12882-025-04727-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,10]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4727"],"URL":"https:\/\/doi.org\/10.1186\/s12882-025-04727-7","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,10]]},"assertion":[{"value":"3 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Review Committee of the First Affiliated Hospital of Jinan University the study protocol (Approval No.: KY-2025-117) and was carried out in accordance with the Declaration of Helsinki. Given the retrospective design of this study, the ethics committee formally granted a waiver of informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"98"}}